SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending amidst strong revenue performance, an influx of new strategic partnerships with global mobile operators, and multiple analyst price target upgrades. The community is actively celebrating this commercial validation and robust financial runway, anticipating a short squeeze and continued upward momentum for its direct-to-device satellite network.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is surging as investors eagerly await imminent Phase 3 REGAL trial results for its AML therapy, GPS, anticipating groundbreaking success that could trigger a significant short squeeze or major pharma buyout. The community believes extended trial duration and previous data signal strong patient outcomes, positioning the stock for a major repricing.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is trending as investors grapple with uncertainty over its release from government conservatorship, fueled by recent directives for substantial mortgage bond purchases that suggest continued federal control over privatization. Community discussion highlights frustration over perceived delays and potential share dilution, while long-term holders maintain optimism due to the company's consistent profitability.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is making waves with its transformative acquisition of Covelya Group, a deal poised to establish it as a dominant force in subsea technology and integrated underwater autonomy solutions. The community is actively debating the short-term impact of share dilution versus the substantial long-term growth and strategic advantages this vertical integration brings, especially given rising defense spending.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending following key regulatory clearances for its high-purity graphene in major global markets, alongside an operational production facility. The community is buzzing with enthusiasm over the company's unique material technology and strategic positioning to capture significant demand across diverse industries, eagerly anticipating upcoming commercial milestones.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending after reporting solid quarterly results that were overshadowed by a conservative fiscal year 2027 guidance, causing a significant stock dip. While bulls see the new $400 million share repurchase and AI-driven platform potential as strong buy signals, bears point to slowing growth and increased competition within the software sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending amidst community debate over competitor Roche's Fenebrutinib trial data, contrasting its safety concerns with Briumvi's strong long-term efficacy, recently reinforced by JAMA Neurology publication. The stock is also gaining visibility from a national MS awareness campaign with Christina Applegate, while investors await upcoming earnings and discuss the implications of rising short interest.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending after reporting a significant Q4 2025 EPS beat, strong revenue growth, and positive 2026 guidance, alongside promising R289 pipeline data. Despite these strong financial results and a perceived low valuation, the stock's puzzling market reaction is fueling community frustration, high short interest, and ongoing buyout speculation within the biotech sector.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin (BTC) is trending as it breaks out of consolidation and shows signs of a significant rebound, with community discussion highlighting record short leverage poised for an unwind and strong institutional support at key price levels.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending after its Airobotics subsidiary secured an initial $20 million government contract for AI-driven autonomous border defense, though the community expresses frustration over perceived market manipulation and heavy shorting preventing the stock from fully reflecting this news and broader sector tailwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While Microbot's corporate headquarters are in the U.S., the heart of its technical development is its facility in the Caesarea Business and Industrial Park in Israel.</li><li>The company said it maintains sufficient Liberty system inventory in the U.S. to support current customers and is building additional stock to meet anticipated demand.</li></ul>Israel-founded Microbot Medical Inc. (MBOT) said on Tuesday that it is not experiencing any business disruption due to geopolitical events but is actively building additional stock in the U.S. to meet anticipated demand for its Liberty system.Shares of the company, however, traded 3% lower at the time of writing.<h2 class="st-heading-2">Microbot’s Assurance</h2>Microbot <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/03/3248415/0/en/Microbot-Medical-Confirms-Continued-Operational-and-Commercial-Stability-Amid-Current-Geopolitical-Event.html">said</a> that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual and both internal operations and the lead manufacturing partner remaining fully functional.The FDA approved Microbot’s Liberty Endovascular Robotic System, a single-use, remotely operated robotic system for peripheral endovascular procedures, in September 2025. The company said that its commercial focus is now on the U.S. Market which is managed by its U.S.-based commercial team in Hingham.“This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned,” the company said. It added that the company maintains sufficient inventory in the U.S. to support current customers and is building additional stock to meet anticipated demand. The additional stock is being built through the company's U.S.-based third party logistics partner, it said.“The Company is closely monitoring the situation in the Middle East to ensure the ongoing well-being of its employees and to ensure uninterrupted support for customers, reinforcing its commitment to operational excellence,” it added.While Microbot's corporate headquarters are in the U.S., the heart of its technical development is its facility in the Caesarea Business and Industrial Park in Israel.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around MBOT stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/MBOT">MBOT stock</a> has risen 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mdb-stock-sees-biggest-single-day-decline-on-record-wall-street-cuts-price-targets-on-slower-atlas-growth-and-cautious-outlook/cZdekxtRIPK">MDB Stock Sees Biggest Single-Day Decline On Record: Wall Street Cuts Price Targets On Slower Atlas Growth And Cautious Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company

Microbot said on Tuesday that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual. 

Equity

Microbot said on Tuesday that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual. 


<ul class="summary-bullets"><li>Atara said that its partner Pierre Fabre Pharmaceuticals submitted a briefing to the FDA addressing its concerns.&nbsp;</li><li>Atara had transferred its application seeking approval for tabelecleucel to a U.S. pharma unit of Pierre Fabre Laboratories in November.</li></ul>Shares of Atara Biotherapeutics, Inc. (ATRA) rose 7% on Tuesday after the company said that its partner has sought a meeting with the U.S. Food and Drug Administration to address the concerns raised by the agency while it refused approval for its immunotherapy tabelecleucel in January. &nbsp;FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (PTLD) earlier this year. &nbsp;The FDA said in a letter to the company that it is unable to approve the application in present form, stating that the trial conducted by the company is not adequate to provide evidence of effectiveness for accelerated approval. The authority also stated that the trial’s interpretability is confounded due to trial study design, conduct, and analysis.<h2 class="st-heading-2">Atara Pushes Back</h2>On Tuesday, Atara <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260303134105/en/Atara-Biotherapeutics-Provides-Regulatory-Update-on-Tabelecleucel">said</a> that its partner Pierre Fabre Pharmaceuticals submitted a briefing to the FDA addressing its concerns and provided additional context and clarification that the study was indeed adequate, well-controlled, and sufficient to support the tabelecleucel application.The firm also provided summaries of updated, longer-term efficacy data from the study, additional supportive data from the tab-cel development program and post-marketing data in Europe that will be included in a potential resubmission, it said.“With our partners at Pierre Fabre Pharmaceuticals, we are eager to engage in a constructive discussion with the FDA to reach a path forward for tabelecleucel,” said Atara CEO Cokey Nguyen while also noting the “ultra-rare nature” of PTLD.Epstein-Barr Virus (EBV)-positive Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious, often life-threatening complication after organ or stem cell transplantation, characterized by uncontrolled growth of EBV-infected B-cells due to suppressed immunity, ranging from mononucleosis-like illness to aggressive lymphoma.Atara had transferred its application seeking approval for tabelecleucel to a U.S. pharma unit of Pierre Fabre Laboratories in November.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATRA rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/ATRA">ATRA stock</a> has fallen 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-jeff-schmid-says-apex-bank-does-not-have-room-to-be-complacent-about-inflation-report/cZdekrARIP0">Fed’s Jeff Schmid Says Apex Bank Does Not Have Room To Be ‘Complacent’ About Inflation: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection

FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease earlier this year.

<ul class="summary-bullets"><li>One&nbsp;Stocktwits user said that closing of Hormuz strait was the worst case scenario for oil.&nbsp;</li><li>The strait serves as the world's most important oil export route, linking major Gulf oil producing nations.&nbsp;</li><li>Analysts at UBS expect the rise in crude oil prices to reverse at least partially in their base case scenario, according to a note.&nbsp;</li></ul>Battalion Oil (<a href="https://stocktwits.com/symbol/BATL">BATL</a>) shares jumped 123% on Monday, and saw volatility halts&nbsp;amid rising oil prices&nbsp;due to the ongoing war&nbsp;among U.S., Israel, and Iran.&nbsp;&nbsp;At the time of writing stock was up 1.6% to $11.96 in extended hours of trading after closing 113% higher.&nbsp;<h2 class="st-heading-2">What Is Retail Thinking?</h2>On Stocktwits, retail sentiment around BATL stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.One user on Stocktwits said that closing of the Strait of Hormuz was the ‘worst case scenario’ for oil.&nbsp;<stembedurl>https://stocktwits.com/mark3rd/message/646357490</stembedurl>One bullish user,&nbsp;however, predicted that the stock will open gap up on Tuesday.&nbsp;<stembedurl>https://stocktwits.com/StocktraderOO7/message/646361943</stembedurl>Another user predicted that the stock rise will continue if the price prediction of oil per barrel&nbsp;goes&nbsp;$80+.<stembedurl>https://stocktwits.com/rekked87/message/646360511</stembedurl><h2 class="st-heading-2">Strait Of Hormuz Closed</h2>Iran’s Revolutionary Guards commander has said that the&nbsp;Strait of Hormuz, the world’s most critical oil route, is closed and Iran will set any ship trying to pass on fire, The Guardian <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.theguardian.com/world/live/2026/mar/02/us-israel-war-iran-live-updates-attacks-strikes-tehran-lebanon-beirut-hezbollah-dubai-latest-news?page=with:block-69a5f3d28f0863f6a3f00095">reported</a>, citing Iranian state media.&nbsp;Reuters earlier <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/middle-east/irans-revolutionary-guards-tell-ships-passage-through-strait-hormuz-not-allowed-2026-02-28/">reported</a> that an official from the European Union's naval mission Aspides said that vessels have been receiving VHF transmission from Iran's Revolutionary Guards saying "no ship is allowed to pass the Strait of Hormuz."The strait serves as the world's most important oil export route, linking major Gulf oil producers—including Saudi Arabia, Iran, Iraq, and the United Arab Emirates—to the Gulf of Oman and the Arabian Sea.<h2 class="st-heading-2">UBS Commentary On Oil</h2>Analysts at UBS expect the rise in crude oil prices to reverse at least partially in their base case scenario, according to a note, as per TheFly.&nbsp;“Markets may be volatile over the coming weeks but would likely thereafter start to refocus on positive global economic fundamentals. This would be in line with the impact of most geopolitical shocks in recent history,” UBS told investors.&nbsp;Shares of BATL have risen 682% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A crane ship helps other vessels searching for oil and natural gas near the oil platform offshore the Red Sea in Ras Behar region, Egypt.

Battalion Oil Stock More Than Doubles — Retail Sees Hormuz Strait Closure As The ‘Worst Case Scenario’ For Oil

Iran’s Revolutionary Guards commander has reportedly said that the Strait of Hormuz is closed, The Guardian reported. citing Iranian state media. 

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

<ul class="summary-bullets"><li>The company said that Hawaiian Electric’s net income for the fourth quarter of 2025 was $44 million compared to net income of $46 million in the fourth quarter of 2024.&nbsp;</li><li>The holding and other companies’ net loss was $45 million in 2025 compared to $96 million in 2024.</li></ul>Hawaiian Electric Industries shares rose on Friday after it swung to profit in the fourth quarter compared to the&nbsp;loss of $68 million reported in the year-ago quarter.&nbsp;Shares in the company jumped 1.5% at the time of writing.&nbsp;&nbsp;Hawaiian Electric Industries and its other companies’ net loss was $45 million in 2025 compared to $96 million in 2024. The lower net loss for the year was primarily due to expenses taken in 2024 related to strategic reviews, and lower Maui wildfire expenses,&nbsp;the company said.<h2 class="st-heading-2">Q4 Earnings</h2>The company said that its fourth quarter 2025 net income was $40 million, or $0.23 per share, compared to a net loss of $68 million, or $0.40 per share in 2024. Analysts on average expected a profit of $0.4 per share, as per data from fiscal.ai.&nbsp;“Our core utility business continued to perform well in 2025, operating efficiently and maintaining financial strength while making the critical investments necessary to ensure safe, reliable and resilient service to our communities,” said&nbsp;CEO Scott Seu.&nbsp;“We also saw the utility reaching a 37% renewable portfolio standard in 2025, putting us on track to meet the 40% RPS by 2030 statutory requirement. HEI continues to be well-positioned to execute our commitment to a stronger, more resilient and more financially healthy future,” he added.&nbsp;<h2 class="st-heading-2">Hawaiian Electric</h2>The company said that its unit Hawaiian Electric’s net income for the fourth quarter of 2025 was $44 million compared to net income of $46 million in the fourth quarter of 2024.&nbsp;The company said that the decrease was primarily driven by the pre-tax items including $7 million in higher interest expense, $1 million in higher O&amp;M expenses and $1 million in higher depreciation expense.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around HEI trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user wrote, “...they are back on track as they were when the stock was $45, this is an easy buy for me here”.<stembedurl>https://stocktwits.com/JMJTrading/message/646163982</stembedurl>Shares in the company have risen 46.2% over the past year.&nbsp;

In this photo illustration, the Hawaiian Electric Industries logo is seen on a smartphone screen

Hawaiian Electric Shares Are Higher Today – Know Why

The company said that its fourth quarter 2025 net income was $40 million, or $0.23 per share, compared to a net loss of $68 million, or $0.40 per share in 2024.

<ul class="summary-bullets"><li>After the spinoff, Trump Media will own TAE’s nuclear fusion business along with some of its own assets.</li><li>Trump Media would subsequently be merged with Texas Ventures III, a Nasdaq-listed blank check vehicle.</li><li>The spinoff announcement comes within months of Trump Media announcing plans to merge with TAE, a nuclear fusion company founded in 1998.</li></ul>Trump Media &amp; Technology Group Corp. (DJT) on Friday announced that it is currently undertaking discussions with TAE Technology Inc. and Texas Ventures Acquisition III Corp. (TVA) to spin off its social media platform, Truth Social.The company stated that discussions are ongoing to consider spinning off the platform into a new publicly-traded company. The company stated that discussions are ongoing to consider spinning off the platform into a new publicly-traded company.<a href="https://stocktwits.com/symbol/DJT">Trump Media shares</a> were up 0.3% in Friday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory, with message volumes at ‘high’ levels.<h2 class="st-heading-2">What Will Happen To DJT’s Existing Shareholders?</h2>Trump Media added that the shares of Truth Social would be distributed to its shareholders of record prior to the closing of the merger with TAE.Thereafter, the social media platform would be merged with Texas Ventures III, a Nasdaq-listed blank check vehicle.Following the spinoff, Trump Media will own TAE’s nuclear fusion business along with some of its own assets, the company said.Earlier this month, Trump Media also issued an update on its digital token initiative, stating that it is collaborating with broker participants, intermediaries, and other stakeholders to ensure an accurate and complete count of DJT shareholders as of the record date of Feb. 2, 2026.The company stated that this was to facilitate the participation of eligible shareholders in its digital token initiative.<h2 class="st-heading-2">Trump Media’s Merger With TAE</h2>The spinoff announcement comes within months of Trump Media announcing plans to merge with TAE, a nuclear fusion company founded in 1998.The two companies signed the merger agreement in December 2025 as part of an all-stock transaction valued at more than $6 billion.<a href="https://stocktwits.com/symbol/DJT">DJT stock</a> is down 17% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wbd-stock-double-downgrade-after-netflix-pulls-out-of-bidding-war-with-psky/cZTciKoRIT2">WBD Gets A Double Downgrade After Netflix Pulls Out Of Bidding War With Paramount Skydance — Here's What Analysts Said</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Truth Social logo is seen displayed on a smartphone with a Trump Media & Technology Group (TMTG) logo in the background.

Truth Social Spinoff — DJT Stock Rises As Trump Media Explores Public Listing Deal For The Platform

Trump Media added that the shares of Truth Social would be distributed to its shareholders of record prior to the closing of the merger with TAE.

<ul class="summary-bullets"><li>Searchlight and Abry will acquire all issued and outstanding shares of KORE common stock not already owned by them at an all-cash price of $9.25 per share.</li><li>This represents a premium of about 85% compared to KORE’s closing price on Thursday.</li><li>KORE stated that, post-acquisition, it will be taken private while continuing to focus on its current Internet of Things consumer product portfolio.</li></ul>KORE Group Holdings Inc. (KORE) stock ripped nearly 80% in Friday’s pre-market trade after the company announced that it has entered into a definitive agreement to be acquired by Searchlight Capital Partners and Abry Partners.KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own. The all-cash transaction is valued at nearly $726 million.Searchlight and Abry will acquire all issued and outstanding shares of KORE common stock not already owned by them at an all-cash price of $9.25 per share.This represents a premium of about 85% compared to KORE’s closing price on Thursday.<h2 class="st-heading-2">KORE To Be Taken Private</h2>KORE stated that, post-acquisition, it will be taken private while continuing to focus on its current Internet of Things consumer product portfolio. It expects the transaction to close in the third quarter (Q3) of 2026.“Both firms have an exceptional track record of helping their portfolio companies foster the growth and innovation required to be an industry leader with a loyal and satisfied customer base,” said KORE CEO Ron Totton.While Searchlight is a global investment firm with $18 billion in assets under management, Abry is a private equity firm managing about $16 billion across its funds.The two firms had sent a non-binding letter to KORE in November 2025 to acquire all of the company's shares they don’t already own for a cash consideration of $5 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KORE">KORE Group</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.One user on Stocktwits called the acquisition news very good, while adding that volumes could push the stock to $10, nearly doubling it from Thursday’s closing price.<stembedurl>https://stocktwits.com/Josema66/message/646080395</stembedurl><a href="https://stocktwits.com/symbol/KORE">KORE stock</a> is up 19% year-to-date and 116% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wbd-stock-double-downgrade-after-netflix-pulls-out-of-bidding-war-with-psky/cZTciKoRIT2">WBD Gets A Double Downgrade After Netflix Pulls Out Of Bidding War With Paramount Skydance — Here's What Analysts Said</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KORE Stock Is Ripping Pre-Market Today After Company Agrees To A Deal To Take It Private

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

<ul class="summary-bullets"><li>B. Riley upgraded Applied Optoelectronics to ‘Neutral’ from ‘Sell’ and raised the price target to $54 from $15.</li><li>The brokerage expects 800G products to be a key growth driver from Q2.</li><li>Applied Optoelectronics also signed an equity distribution to raise up to $250 million.</li></ul>Shares of Applied Optoelectronics (AAOI) surged 20% in pre-market trading on Friday, putting the stock on track for its highest open since October 2017, after a bullish analyst call amplified momentum from its stronger-than-expected fourth-quarter results.The semiconductor company’s Q4 revenue jumped 34% to $134.3 million, beating Wall Street’s estimates of $128.2 million, according to Fiscal.ai data. Applied Optoelectronics posted a loss of $0.03 per share, which was below the consensus estimate of $0.11 per share.For the first quarter of fiscal 2026, the company expects revenue between $150 million and $165 million, and a non-GAAP net loss of $7.0 million to $0.3 million, or a loss of $0.09 per share to breakeven.According to a SEC filing on Thursday, Applied Optoelectronics entered into an equity distribution agreement with Raymond James &amp; Associates and Needham &amp; Company, enabling it to raise up to $250 million through at-the-market sales of its common stock, with the two firms acting as agents.<h2 class="st-heading-2">B. Riley Bets On AAOI’s 800G Product Pipeline</h2>After the Q4 earnings, B. Riley upgraded Applied Optoelectronics to ‘Neutral’ from ‘Sell’ and significantly raised the price target to $54 from $15, according to The Fly.The brokerage attributed the upgrade to ongoing strength in 400G (Gigabit Ethernet), where demand remains robust, led by steady order flow from key customer Amazon (AMZN). B. Riley also expects 800G transceivers to be a key growth driver from the second quarter of fiscal 2026.“We have begun ramping up production of this 800G module in anticipation of a strong volume ramp starting in Q2. Focus demand for 800G module are projected to exceed our production capacity through mid-2027. We are working to add additional capacity to meet this demand. 800G is expected to dominate our revenue beginning in Q2,” Chairman and CEO Thompson Lin, said in a call with analysts.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>The results got retail investors buzzing, with message volumes on Stocktwits increasing by around 167% over a 24-hour period. Sentiment for <a href="https://stocktwits.com/symbol/AAOI">AAOI</a> on the platform was ‘bullish.’&nbsp;&nbsp;<img src="https://news.stocktwits-cdn.com/AAOI_jpg_2252fe6fae.webp" alt="AAOI.jpg">One user expects the stock to soar over the coming months, primarily due to the company’s guidance.<stembedurl>https://stocktwits.com/RocketQueen/message/646046256</stembedurl>Another user said they would consider initiating new positions if the stock experiences a pullback.<stembedurl>https://stocktwits.com/drteamp/message/646047331</stembedurl>However, one bearish user called the price action “crazy” for a company not making a profit.<stembedurl>https://stocktwits.com/jimmywestone317/message/646056001</stembedurl>Year-to-date, the stock has surged more than 76%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Workers use microscopes in the production facility at Applied Optoelectronics Tuesday, May 10, 2016, in Houston.  (Photo by Karen Warren/Houston Chronicle via Getty Images)

AAOI Stock On Track To Open At Over 8-Year Highs: B. Riley Upgrade, Retail Optimism Drive Rally 

The company reported a 34% jump in fourth-quarter revenue to $134.3 million, beating Wall Street’s estimates of $128.2 million, according to Fiscal.ai data.

AAOI Stock Set For Highest Open In Over 8 Years As 800G Ramp Sparks Analyst Upgrade, Retail Buzz

<ul class="summary-bullets"><li>Together the companies expect to deliver approximately 1 gigawatt of near-term IT capacity with a pathway to more than 2.5 gigawatts.</li><li>The campuses will be designed to operate both Bitcoin mining and AI compute.</li><li>MARA said its net loss was $1.7 billion, or $4.52 per diluted share, in Q4 2025, compared to net income of $528.3 million, or $1.24 per diluted share, in Q4 2024.</li></ul>MARA Holdings’ stock rallied 16.5% during extended hours of trading on Thursday after it reported its fourth quarter results and announced a strategic partnership with Starwood.&nbsp;MARA Holdings announced it has entered into a strategic agreement with Starwood Capital Group and their dedicated data center development platform Starwood Digital Ventures. Together, the companies expect to deliver approximately 1 gigawatt of near-term IT capacity with a pathway to more than 2.5 gigawatts.“MARA’s power rich sites give customers what they need most: predictable access to energy at scale,” said Fred Thiel, MARA’s Chairman and CEO. “Our partnership with Starwood will allow us to turn that power certainty into capacity certainty, so customers can run diverse workloads close to their data and users”.&nbsp;The companies will prioritize sites with access to low-cost energy, strong interconnection positions, and clear pathways to scale. These campuses will be designed to operate both Bitcoin mining and AI compute, giving MARA the ability to toggle workloads in response to market pricing and customer demand.&nbsp;<h2 class="st-heading-2">Q4 Results</h2>MARA said its revenues decreased 6% to $202.3 million in the fourth quarter (Q4) of 2025 from $214.4 million in the year-ago quarter. It said that the decrease was primarily driven by a 14% decrease in the average price of bitcoin mined over the quarter.It said its net loss was $1.7 billion, or $4.52 per diluted share, in Q4 2025 compared to net income of $528.3 million, or $1.24 per diluted share, in Q4 2024. Net loss during the quarter includes a $1.5 billion loss on fair value of digital assets.MARA said that in 2026 it expects to continue to monetize bitcoin opportunistically to enhance&nbsp;its financial flexibility, including to provide liquidity or to fund capital projects and other initiatives.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen nearly 19% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Marathon Digital Holdings (MARA) logo is displayed on a smartphone screen.

MARA Stock Is Rallying Today – What Is All The Buzz About?

MARA Holdings announced it has entered into a strategic agreement with Starwood Capital Group and their dedicated data center development platform Starwood Digital Ventures.

<ul class="summary-bullets"><li>Ocugen is advancing OCU400 to address all gene mutations associated with retinitis pigmentosa (RP) with a single, one-time injection.</li><li>The company is looking to make a rolling Biologics License Application for OCU400.&nbsp;</li><li>In a previous study, all subjects treated with OCU400 showed improvement or preservation in visual function compared to untreated eyes after two years.</li></ul>Shares of Ocugen Inc. (OCGN) rose nearly 5% on Wednesday after the company said that it plans to start seeking the approval of the U.S. Food and Drug Administration (FDA) for its experimental therapy, OCU400, starting this year.Ocugen is advancing OCU400 to address all gene mutations associated with retinitis pigmentosa (RP) with a single, one-time injection.“We plan to begin the rolling submission for the OCU400 Biologics License Application this year and potentially provide a treatment option for the 98% of RP patients for whom no therapy exists,” the company said in a post on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7432479854509400064/">LinkedIn</a>.<h2 class="st-heading-2">About Retinitis pigmentosa</h2>Retinitis pigmentosa (RP) is a group of rare, inherited genetic disorders causing slow, progressive retinal degeneration and vision loss, typically starting with night blindness and peripheral vision loss (tunnel vision) in childhood or young adulthood. Ocugen estimates the condition affects about 300,000 people in the U.S. and Europe combined.In a previous study including 18 subjects, OCU400 demonstrated sustained favorable safety and tolerability. All the treated subjects showed improvement or preservation in visual function compared to untreated eyes after two years, the company said.In November, the company said that it is looking to initiate an application to the FDA for approval of the therapy in the first half of 2026. Ocugen is looking to make a rolling Biologics License Application, an FDA-approved process that allows pharmaceutical companies to submit completed sections or modules of their application for review as they are finished, rather than waiting to submit the entire document at once.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around OCGN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-stock-plummets-after-partner-united-therapeutics-unveils-new-category-killer-product/cZRyOedRIGN">MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did OCGN Stock Rise Today?

Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year. 

Current Price	$215.50
Prev Close	$214.36
Open	$216.06
Dividend Yield	N/A
50-Day Moving Average	$216.48
Beta	N/A
Avg. Volume	497,197.92
PE Ratio	N/A

52-Week High	$223.64
52-Week Low	$146.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF